8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 3, 2022)

Filed March 3, 2022For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) announced on March 1st and 2nd, 2022, updates regarding their previously announced cash tender offers to purchase outstanding notes. These offers encompass notes issued by BMY itself and its wholly-owned subsidiary, Celgene Corporation. The company has provided early participation results and announced an upsizing of these offers, indicating a proactive approach to managing its debt obligations. Furthermore, BMY has confirmed the early settlement and the accepted amounts along with the pricing terms for these tender offers. This move suggests that the company is taking advantage of favorable market conditions or strategic financial management to refinance or reduce its debt. Investors should note that these tender offers are governed by the terms outlined in the Offer to Purchase dated February 15, 2022, and any subsequent amendments.

Key Highlights

  • 1BMY announced early participation results for its cash tender offers on March 1, 2022.
  • 2The company announced an upsizing of these cash tender offers.
  • 3Early settlement and pricing terms for the tender offers were announced on March 2, 2022.
  • 4The tender offers include notes issued by Bristol Myers Squibb and its subsidiary, Celgene Corporation.
  • 5These actions are related to the company's management of its outstanding debt obligations.
  • 6The offers are subject to the terms detailed in the Offer to Purchase dated February 15, 2022.

Frequently Asked Questions

Bristol Myers Squibb is conducting cash tender offers to purchase notes that it has issued, as well as notes issued by its wholly-owned subsidiary, Celgene Corporation. The company has provided updates on participation, upsizing, settlement, and pricing terms for these offers.

These tender offers are part of Bristol Myers Squibb's debt management strategy. By offering to purchase its outstanding notes, the company may be looking to refinance its debt at potentially more favorable rates, reduce its overall debt load, or optimize its capital structure.

The company issued press releases on March 1, 2022 (announcing early participation results, upsizing, and early settlement) and March 2, 2022 (announcing accepted amounts and pricing terms). The full details and terms of the offers are outlined in the Offer to Purchase dated February 15, 2022, which may be amended.

The upsizing of the offers suggests that BMY received significant interest from noteholders and is willing to purchase a larger principal amount of notes. Early settlement indicates the company is moving efficiently to complete the transactions, potentially to capitalize on current financial conditions or meet specific financial objectives.